Navidea Biopharmaceuticals Inc is a precision medicine company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents.
| Website: | www.navidea.com |
| Email: | info@neoprobe.com |
| Main Phone: | +1 614 793-7500 |
| Address: | 5600 Blazer Parkway |
| Address 2: | Suite 200 |
| State: | OH |
| City / Town: | Dublin |
| Country: | USA |
| Postal Code: | 43017-7550 |
| Exchange: | AMX |
| Employees: | 57 |
| NAICS: | In-Vitro Diagnos |
| Last Price 0.39 | Change $ -0.0137 | Change % -3.37 | Tick N/A |
| Bid 0. | Bid Size 0.00 | Ask 0. | Ask Size 0.00 |
| Open 0.40 | High 0.40 | Low 0.39 | Prev Close 0.41 |
| Last Trade | Volume 230,153 | 52 Wk Hi 1.16 | 52 Wk Low 0.26 |
| Market Cap 63.8 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 162,206,646.00 | EPS (TTM) 0.47 | PE Ratio 0.90 | Exchange NYSE American |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 2 | 17 |
| Number of Buys | 2 | 13 |
| Number of Sells | 0 | 4 |
| Net Activity | 71580 | 267660 |
| Last 10 Buys | Shares |
|---|---|
| Gordon A. Troup | 1,000 |
| Brendan A. Ford | 1,000 |
| Michael M. Goldberg | 1,000 |
| Michael M. Goldberg | 1,000 |
| Brendan A. Ford | 1,000 |
| Mark J. Pykett | 1,000 |
| Brent L. Larson | 1,000 |
| Brendan A. Ford | 1,000 |
| Mark J. Pykett | 1,000 |
| Brendan A. Ford | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Frederick O. Cope | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 2.4 | 2.4 | 2.4 | 2.4 |
| Low Target Price Estimate | 2.4 | 2.4 | 2.4 | 2.4 |
| Mean Target Price Estimate | 2.4 | 2.4 | 2.4 | 2.4 |
| Standard Deviation | 0 | 0 | 0 | 0 |
| Date of Most Recent Estimate | 04/05/16 | 04/05/16 | 04/05/16 | 04/05/16 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate changes. | 5 | 2016-08-11 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 50 | 2016-08-11 |
| NT 10-Q | Notification that form 10-Q will be submitted late | 4 | 2016-08-10 |
| 8-K | Report of unscheduled material events or corporate changes. | 10 | 2016-08-04 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2016-07-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2016-07-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2016-07-07 |
| DEFA14A | Additional proxy soliciting materials - definitive | 5 | 2016-07-01 |
| DEF 14A | Official notification to shareholders of matters to be brought to a vote (Proxy) | 44 | 2016-07-01 |
| 8-K | Report of unscheduled material events or corporate changes. | 12 | 2016-06-29 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 0 | 0 | 1 | 1 |
© 2017 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
